Shanghai Henlius Biotech, Sandoz sign pact to collaborate
17/08/2026 02:21
Shanghai Henlius Biotech, Sandoz sign pact to collaborate SHANGHAI, Aug 17 (Reuters) - Shanghai Henlius Biotech 2696.HK has agreed a collaboration pact with Swiss generic drugmaker Sandoz SDZ.S, the Chinese drugmaker told the Hong Kong stock exchange in a filing on Monday.
The aggregate invoiced amount is expected to reach up to $100.50 million in 2026, the company added.
(Reporting by Andrew Silver in Shanghai; Editing by Clarence Fernandez)
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln